Q3 2024 · 13F-HR
Commodore Capital LPholdings as filed
Filed 2024-11-14 · accession 0001831942-24-000009
$1.60B
Reported value
36
Positions
2024-09-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| N5749R100 | 2GH | MERUS N V | $167.4M | 10.5% | 3,350,000 | Common | SOLE |
| 92337R101 | VERA | VERA THERAPEUTICS INC | $109.4M | 6.84% | 2,475,000 | Common | SOLE |
| 98420N105 | XENE | XENON PHARMACEUTICALS INC | $106.3M | 6.64% | 2,700,000 | Common | SOLE |
| 92243G108 | PCVX | VAXCYTE INC | $105.1M | 6.57% | 920,000 | Common | SOLE |
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS INC | $104.7M | 6.54% | 4,100,000 | Common | SOLE |
| 670703107 | NUVL | NUVALENT INC | $96.2M | 6.01% | 940,000 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $81.4M | 5.09% | 7,539,930 | Common | SOLE |
| G01767105 | ALKS | ALKERMES PLC | $81.2M | 5.07% | 2,900,000 | Common | SOLE |
| 834203309 | SLNO | SOLENO THERAPEUTICS INC | $63.6M | 3.98% | 1,260,000 | Common | SOLE |
| 00773J202 | SYRE | SPYRE THERAPEUTICS INC | $58.5M | 3.65% | 1,988,084 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $58.0M | 3.63% | 2,550,124 | Common | SOLE |
| 15117B202 | CLDX | CELLDEX THERAPEUTICS INC NEW | $55.0M | 3.44% | 1,618,937 | Common | SOLE |
| 60255C885 | BRD1EUR | MIND MEDICINE MINDMED INC | $45.5M | 2.84% | 8,000,000 | Common | SOLE |
| 46489V302 | CATX | PERSPECTIVE THERAPEUTICS INC | $44.7M | 2.79% | 3,350,000 | Common | SOLE |
| 67080M103 | NRIX | NURIX THERAPEUTICS INC | $37.1M | 2.32% | 1,650,000 | Common | SOLE |
| N69605108 | PHVS | PHARVARIS N V | $35.4M | 2.21% | 1,911,433 | Common | SOLE |
| 50127T109 | KURA | KURA ONCOLOGY INC | $35.2M | 2.20% | 1,800,000 | Common | SOLE |
| 76243J105 | RYTM | RHYTHM PHARMACEUTICALS INC | $34.1M | 2.13% | 650,000 | Common | SOLE |
| 687604108 | ORKA | ORUKA THERAPEUTICS INC | $33.6M | 2.10% | 1,369,714 | Common | SOLE |
| 04335A105 | ARVN | ARVINAS INC | $29.6M | 1.85% | 1,200,000 | Common | SOLE |
| 15102K100 | CELC | CELCUITY INC | $22.7M | 1.42% | 1,522,332 | Common | SOLE |
| 152309100 | CNTA | CENTESSA PHARMACEUTICALS PLC | $21.6M | 1.35% | 1,350,000 | Common | SOLE |
| 65487U108 | NKTX | NKARTA INC | $21.1M | 1.32% | 4,662,073 | Common | SOLE |
| 68622P109 | ORIC | ORIC PHARMACEUTICALS INC | $20.5M | 1.28% | 2,000,000 | Common | SOLE |
| 12529R107 | CCCC | C4 THERAPEUTICS INC | $19.4M | 1.21% | 3,410,384 | Common | SOLE |
| 88427A107 | — | THIRD HARMONIC BIO INC | $18.4M | 1.15% | 1,360,569 | Common | SOLE |
| 87164F105 | SNDX | SYNDAX PHARMACEUTICALS INC | $17.0M | 1.06% | 885,000 | Common | SOLE |
| 03770N101 | APGE | APOGEE THERAPEUTICS INC | $17.0M | 1.06% | 290,000 | Common | SOLE |
| 00370M103 | ABVX | ABIVAX SA | $14.8M | 0.92% | 1,284,110 | Common | SOLE |
| 45783C200 | TIL | INSTIL BIO INC | $10.2M | 0.63% | 150,929 | Common | SOLE |
| 64135M105 | NGNE | NEUROGENE INC | $8.4M | 0.52% | 200,000 | Common | SOLE |
| G70077105 | PCSC | PERCEPTIVE CAP SOLUTIONS COR | $7.5M | 0.47% | 750,000 | Common | SOLE |
| G4444H101 | BBOT | HELIX ACQUISITION CORP II | $5.2M | 0.33% | 500,000 | Common | SOLE |
| 12674W109 | CABA | CABALETTA BIO INC | $5.2M | 0.32% | 1,100,000 | Common | SOLE |
| 92840H400 | VTGN | VISTAGEN THERAPEUTICS INC | $4.7M | 0.30% | 1,575,000 | Common | SOLE |
| 05338F306 | AVTX | AVALO THERAPEUTICS INC | $4.6M | 0.29% | 483,000 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.